Jose Sandoval Sus, MD

Articles by Jose Sandoval Sus, MD

Spotlighting Emergent CAR T-Cell Therapy in High-Risk B-Cell Lymphomas

August 8th 2025

Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.

Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.

Identifying Limitations to CAR T-Cell Therapies in Large B-Cell Lymphoma

ByJose Sandoval Sus, MD

August 6th 2025

Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.

Latest Updated Articles

Spotlighting Emergent CAR T-Cell Therapy in High-Risk B-Cell Lymphomas
August 8th 2025

Trending on CancerNetwork

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)